Urologix Inc  

(Public, OTCMKTS:ULGX)   Watch this stock  
Find more results for ULGX
0.0949
-0.0054 (-5.36%)
Nov 26 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.06 - 0.09
52 week 0.06 - 0.25
Open 0.08
Vol / Avg. 63,975.00/18,461.00
Mkt cap 2.06M
P/E     -
Div/yield     -
EPS -0.31
Shares 21.67M
Beta 0.97
Inst. own 32%
Feb 2, 2015
Q2 2015 Urologix Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 6, 2014
Urologix Inc Annual Shareholders Meeting
Nov 4, 2014
Q1 2015 Urologix Inc Earnings Call - Webcast
Nov 4, 2014
Q1 2015 Urologix Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -14.47% -53.45%
Operating margin -7.98% -48.68%
EBITD margin - -23.23%
Return on average assets -31.34% -
Return on average equity - -
Employees 61 -
CDP Score - -

Address

14405 21ST AVE N
MINNEAPOLIS, MN 55447
United States - Map
+1-612-4751400 (Phone)
+1-763-4048118 (Fax)

Website links

Description

Urologix, Inc. (Urologix) develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH). These therapies use technology in the treatment of BPH, a disease that affects more than 30 million men worldwide and is the most common prostate problem for men over 50. It markets both the Cooled ThermoTherapy (CTT) product line and the Prostiva Radio Frequency (RF) Therapy System. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate through the use of insulated electrodes deployed from a transurethral scope, ablating targeted prostatic tissue under the direct visualization of the urologist. These focal ablations reduce constriction of the urethra, thereby relieving BPH voiding symptoms. It acquired the worldwide license to the Prostiva RF Therapy System, in September 2011.

Officers and directors

Gregory J. Fluet Chief Executive Officer, Interim Chief Financial Officer and Principal Financial Officer, Director
Age: 45
Lisa A. Ackermann Executive Vice President - Sales and Marketing
Age: 42
Mitchell Dann Independent Non-Executive Chairman of the Board, Lead Director
Age: 54
Christopher R. Barys Independent Director
Age: 48
Sidney W. Emery Jr. Independent Director
Age: 68
Patrick D. Spangler Independent Director
Age: 59